Jump to content

Avistan Showing Better Results in Ongoing Trials for LC


Recommended Posts

October 8, 2004

Genentech Inc. closed down 30 cents, or less than 1 percent, at $47.25 after spending much of the day up about 2 percent on an upgrade from Credit Suisse First Boston. CSFB said Avastin, the company's key colon cancer drug, is likely to post positive results from a late-stage study of its use for lung cancer. Mid-stage trials did not show any significant effect of Avastin in lung cancer patients, but CFSB said the phase III study is more targeted

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.